Investment Rating - The report maintains a positive outlook on the company, indicating that the performance is bottoming out and organic revenue growth is expected to accelerate in the future [2][3]. Core Insights - The company's FY2025 performance met market expectations, with a revenue decline of 10.4% to 26 billion yuan and a net profit drop of 10.3% to 3.9 billion yuan. However, organic revenue showed signs of stabilization with a slight increase of 1.3% in Q4 [3]. - The impact of volume-based procurement on existing products has been fully absorbed by FY2025, paving the way for organic profit growth to accelerate [2][4]. - The management has provided positive guidance for organic business growth in FY2026 and plans to implement an employee stock ownership plan (ESOP) to enhance execution discipline and visibility of long-term growth [3]. Summary by Relevant Sections Financial Performance - FY2025 revenue decreased by 10.4% to 26 billion yuan, while net profit fell by 10.3% to 3.9 billion yuan. The company confirmed 1.8 billion yuan in authorized revenue for FY2025, with approximately 250 million USD pending confirmation for FY2026 [3]. Clinical Development - The collaboration with AstraZeneca is seen as a key driver for mid-term profit growth. The company is optimizing global dose exploration studies for the SYS2082 project and planning critical global trials for the EGFR ADC project [4][5]. - Potential blockbuster products for FY2026 include KN026 (HER2/HER2 bispecific antibody), TG103 (GLP-1 receptor agonist), and albumin-bound paclitaxel II generation [4]. Market Position - The company ranks among the top ten in China's pharmaceutical industry by revenue and has achieved a compound annual growth rate of 3.1% in profitability from 2019 to 2023 [8]. - The revenue breakdown shows that 81.5% comes from finished drugs, with a significant market presence in Asia (91.8% of revenue) [9]. Stock Information - As of March 26, 2026, the stock price was 8.16 HKD, with a market capitalization of 12.5 billion USD. The consensus target price is set at 11.00 HKD [10].

Design Process Overview - The design of the Employee Share Ownership Plan (ESOP) for the Hong Kong Stock Exchange (HKEX) IPO involves five main stages: preliminary planning, structural design, compliance review, establishment and implementation, and post-listing management [2][7]. Structural Design - The choice of legal entity and registration location for the ESOP significantly impacts tax costs, control, and regulatory compliance. Common structures include Limited Partnerships (LP) or corporate entities, with LPs being preferred due to "tax transparency" [3][5]. Compliance Requirements - The ESOP must comply with HKEX and regulatory requirements, including the Listing Rules, which stipulate that the total ESOP shares cannot exceed 10% of the company's issued share capital unless a waiver is granted [4][8]. Strategic Positioning - The core objectives of the ESOP include attracting talent, binding key teams, reducing cash compensation pressure, and enhancing corporate governance. The selection of participants must adhere to the principle of "reasonableness" [5][7]. Scale and Proportion - The total scale of the ESOP is typically set between 5% to 15% of the total share capital before listing, with individual participant holdings generally not exceeding 1% to avoid excessive dilution [5][8]. Funding Sources - Employees usually contribute their own funds, but the company may provide loans under specific conditions. The interest rates on loans must be reasonable and not affect the employees' repayment ability [5][8]. Entity Type Selection - Employees as shareholders must pay corporate income tax (16.5% in Hong Kong) and personal income tax on dividends/capital gains, which may lead to double taxation issues. The choice between LP and corporate structures depends on the need for independent legal status or complex financing [5][8]. Documentation and Internal Approval - Core agreements must be drafted, including the ESOP agreement and Limited Partnership Agreement (if applicable), outlining participant conditions, funding methods, share calculations, lock-up periods, exit mechanisms, and breach handling [6][8]. Ongoing Management - Post-listing, the ESOP must be managed effectively, including annual disclosures of changes in participation, share transfers, and compliance with HKEX requirements [8][10]. Valuation and Tax Optimization - The entry price for the ESOP must be fair to avoid being perceived as "benefit transfer" to employees. Tax optimization strategies should be employed to minimize tax burdens on both the employees and the platform [9][10]. Control Arrangements - Founders or designated management companies typically act as General Partners (GP) to maintain control over the platform, ensuring that employee shareholding does not excessively dilute control [10]. Information Disclosure - Comprehensive disclosure of the ESOP's key information, including purpose, scale, participant criteria, valuation methods, lock-up periods, and exit mechanisms, is required in the prospectus and ongoing reports to maintain investor confidence [10].